We understand that, earlier today, the European Commission (EC) approved radium-223 dichloride (Xofigo®) for the treatment of men with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastases.
Radium-223 was approved for essentially the same indication in the USA back in May this year. The actual availability of this drug to most patients in individual European nations may take some time while governments negotiate pricing with the manufacturers. A media release issued by Bayer is available on line.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, CRPC, metastatic, radium-223, Xofigo |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply